23 results on '"Burchell, Ann N."'
Search Results
2. Preventative behaviours and COVID-19 infection in a Canadian cohort of people living with HIV
- Author
-
Hammond, Keely, Lee, Terry, Vulesevic, Branka, Singer, Joel, Needham, Judy, Burchell, Ann N., Samji, Hasina, Walmsley, Sharon, Hull, Mark, Jenabian, Mohammad-Ali, Routy, Jean-Pierre, Margolese, Shari, Mandarino, Enrico, Anis, Aslam H., Cooper, Curtis L., and Costiniuk, Cecilia T.
- Published
- 2023
- Full Text
- View/download PDF
3. A national recruitment strategy for HIV-serodiscordant partners living in Canada for the Positive Plus One study: a mixed-methods study
- Author
-
Xi, Min, Bullock, Sandra, Mendelsohn, Joshua B., Iveniuk, James, Moravan, Veronika, Burchell, Ann N., Tan, Darrell H. S., Daftary, Amrita, Thompson, Tamara, Lebouché, Bertrand, Bisaillon, Laura, Myers, Ted, and Calzavara, Liviana
- Published
- 2022
- Full Text
- View/download PDF
4. Community perspectives on ideal bacterial STI testing services for gay, bisexual, and other men who have sex with men in Toronto, Canada: a qualitative study
- Author
-
Rana, Jayoti, Burchell, Ann N., Wang, Susan, Logie, Carmen H., Lisk, Ryan, and Gesink, Dionne
- Published
- 2022
- Full Text
- View/download PDF
5. Influence of previous experience with and beliefs regarding anal cancer screening on willingness to be screened among men living with HIV
- Author
-
Gillis, Jennifer L., Grennan, Troy, Grewal, Ramandip, Ogilvie, Gina, Gaspar, Mark, Grace, Daniel, Lofters, Aisha, Raboud, Janet M., Saarela, Olli, MacPherson, Paul, Rosenes, Ron, Salit, Irving E., and Burchell, Ann N.
- Published
- 2022
- Full Text
- View/download PDF
6. Patterns of changing pregnancy intentions among women living with HIV in Canada
- Author
-
Skerritt, Lashanda, Kaida, Angela, O’Brien, Nadia, Burchell, Ann N., Bartlett, Gillian, Savoie, Édénia, Boucoiran, Isabelle, Gormley, Rebecca, Kestler, Mary, Money, Deborah, Loutfy, Mona, and de Pokomandy, Alexandra
- Published
- 2021
- Full Text
- View/download PDF
7. Patient perspectives on the implementation of routinised syphilis screening with HIV viral load testing: Qualitative process evaluation of the Enhanced Syphilis Screening Among HIV-positive Men trial
- Author
-
MacKinnon, Kinnon R, Grewal, Ramandip, Tan, Darrell HS, Rousseau, Rodney, Maxwell, John, Walmsley, Sharon, MacPherson, Paul A, Rachlis, Anita, Andany, Nisha, Mishra, Sharmistha, Allen, Vanessa G, and Burchell, Ann N.
- Published
- 2021
- Full Text
- View/download PDF
8. Effectiveness of confidential reports to physicians on their prescribing of antipsychotic medications in nursing homes
- Author
-
Ivers, Noah M., Taljaard, Monica, Giannakeas, Vasily, Reis, Catherine, Mulhall, Cara L., Lam, Jonathan M.C., Burchell, Ann N., Lebovic, Gerald, and Bronskill, Susan E.
- Published
- 2020
- Full Text
- View/download PDF
9. Economic barriers, evidentiary gaps, and ethical conundrums: a qualitative study of physicians’ challenges recommending HPV vaccination to older gay, bisexual, and other men who have sex with men
- Author
-
Grace, Daniel, Gaspar, Mark, Rosenes, Ron, Grewal, Ramandip, Burchell, Ann N., Grennan, Troy, and Salit, Irving E.
- Published
- 2019
- Full Text
- View/download PDF
10. Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients.
- Author
-
Antoniou, Tony, Szadkowski, Leah, Walmsley, Sharon, Cooper, Curtis, Burchel, Ann N., Bayoumi, Ahmed M., Montaner, Julio S. G., Loutfy, Mona, Klein, Marina B., Machouf, Nima, Tsoukas, Christos, Wong, Alexander, Hogg, Robert S., Raboud, Janet, Burchell, Ann N, and Canadian Observational Cohort (CANOC) collaboration
- Subjects
ATAZANAVIR ,HIV-positive persons ,RITONAVIR ,HIV protease inhibitors ,VIROLOGY ,COMBINATION drug therapy ,COMPARATIVE studies ,HIV ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,RESEARCH funding ,EVALUATION research ,RETROSPECTIVE studies ,ANTI-HIV agents ,THERAPEUTICS - Abstract
Background: Atazanavir/ritonavir and darunavir/ritonavir are common protease inhibitor-based regimens for treating patients with HIV. Studies comparing these drugs in clinical practice are lacking.Methods: We conducted a retrospective cohort study of antiretroviral naïve participants in the Canadian Observational Cohort (CANOC) collaboration initiating atazanavir/ritonavir- or darunavir/ritonavir-based treatment. We used separate Fine and Gray competing risk regression models to compare times to regimen failure (composite of virologic failure or discontinuation for any reason). Additional endpoints included virologic failure, discontinuation due to virologic failure, discontinuation for other reasons, and virologic suppression.Results: We studied 222 patients treated with darunavir/ritonavir and 1791 patients treated with atazanavir/ritonavir. Following multivariable adjustment, there was no difference between darunavir/ritonavir and atazanavir-ritonavir in the risk of regimen failure (adjusted hazard ratio 0.76, 95% CI 0.56 to 1.03) Darunavir/ritonavir-treated patients were at lower risk of virologic failure relative to atazanavir/ritonavir treated patients (aHR 0.50, 95% CI 0.28 to 0.91), findings driven largely by high rates of virologic failure among atazanavir/ritonavir-treated patients in the province of British Columbia. Of 108 discontinuations due to virologic failure, all occurred in patients starting atazanavir/ritonavir. There was no difference between regimens in time to discontinuation for reasons other than virologic failure (aHR 0.93; 95% CI 0.65 to 1.33) or virologic suppression (aHR 0.99, 95% CI 0.82 to 1.21).Conclusions: The risk of regimen failure was similar between patients treated with darunavir/ritonavir and atazanavir/ritonavir. Although darunavir/ritonavir was associated with a lower risk of virologic failure relative to atazanavir/ritonavir, this difference varied substantially by Canadian province and likely reflects regional variation in prescribing practices and patient characteristics. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
11. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy.
- Author
-
Rossi, Carmine, Raboud, Janet, Walmsley, Sharon, Cooper, Curtis, Antoniou, Tony, Burchell, Ann N., Hull, Mark, Chia, Jason, Hogg, Robert S., Moodie, Erica E. M., Klein, Marina B., and Canadian Observational Cohort (CANOC) Collaboration
- Subjects
ANTIRETROVIRAL agents ,AIDS treatment ,HIV-positive persons ,MIXED infections ,KIDNEY diseases ,HIV infection complications ,HIV infection epidemiology ,CHRONIC kidney failure ,GLOMERULAR filtration rate ,HEPATITIS C ,HEPATITIS viruses ,LONGITUDINAL method ,RESEARCH funding ,PROPORTIONAL hazards models ,DISEASE complications - Abstract
Background: Combination antiretroviral therapy (cART) has reduced mortality from AIDS-related illnesses and chronic comorbidities have become prevalent among HIV-infected patients. We examined the association between hepatitis C virus (HCV) co-infection and chronic kidney disease (CKD) among patients initiating modern antiretroviral therapy.Methods: Data were obtained from the Canadian HIV Observational Cohort for individuals initiating cART from 2000 to 2012. Incident CKD was defined as two consecutive serum creatinine-based estimated glomerular filtration (eGFR) measurements <60 mL/min/1.73m2 obtained ≥3 months apart. CKD incidence rates after cART initiation were compared between HCV co-infected and HIV mono-infected patients. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using multivariable Cox regression.Results: We included 2595 HIV-infected patients with eGFR >60 mL/min/1.73m2 at cART initiation, of which 19% were HCV co-infected. One hundred and fifty patients developed CKD during 10,903 person-years of follow-up (PYFU). The CKD incidence rate was higher among co-infected than HIV mono-infected patients (26.0 per 1000 PYFU vs. 10.7 per 1000 PYFU). After adjusting for demographics, virologic parameters and traditional CKD risk factors, HCV co-infection was associated with a significantly shorter time to incident CKD (HR 1.97; 95% CI: 1.33, 2.90). Additional factors associated with incident CKD were female sex, increasing age after 40 years, lower baseline eGFR below 100 mL/min/1.73m2, increasing HIV viral load and cumulative exposure to tenofovir and lopinavir.Conclusions: HCV co-infection was associated with an increased risk of incident CKD among HIV-infected patients initiating cART. HCV-HIV co-infected patients should be monitored for kidney disease and may benefit from available HCV treatments. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
12. Enhanced syphilis screening among HIV-positive men (ESSAHM): a study protocol for a clinic-randomized trial with stepped wedge design.
- Author
-
Burchell, Ann N., Allen, Vanessa G., Grewal, Ramandip, MacPherson, Paul A., Rachlis, Anita, Walmsley, Sharon, Mishra, Sharmistha, Gardner, Sandra L., Raboud, Janet, Cooper, Curtis, Gough, Kevin, Rourke, Sean B., Rousseau, Rodney, Salit, Irving, and Tan, Darrell H. S.
- Subjects
- *
SYPHILIS epidemiology , *DIAGNOSIS of HIV infections , *MEN who have sex with men , *RANDOMIZED controlled trials , *OUTPATIENT services in hospitals , *DIAGNOSIS of syphilis , *SYPHILIS prevention , *HIV infection complications , *CLINICAL trials , *COMPARATIVE studies , *HOMOSEXUALITY , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *MEDICAL screening , *RESEARCH , *RESEARCH funding , *CITY dwellers , *EVALUATION research , *EARLY diagnosis , *MIXED infections - Abstract
Background: The current syphilis epidemic among urban men who have sex with men (MSM) has serious implications for those co-infected with human immunodeficiency virus (HIV). Routine and frequent syphilis screening has the potential to ensure early detection and treatment, minimize disease burden, and help control the ongoing spread of syphilis and HIV. We aim to enhance syphilis screening among HIV-positive men by conducting a clinic-based intervention that incorporates opt-out syphilis testing into routine HIV laboratory evaluation for this population. Trial objectives are to determine the degree to which the intervention (1) increases the detection rate of untreated syphilis, (2) increases screening coverage, (3) increases screening frequency, and (4) reaches men at highest risk according to sexual behaviors.Methods/design: The trial is a pragmatic, stepped wedge cluster-randomized controlled trial that introduces the intervention stepwise across four urban HIV clinics in Ontario, Canada. The intervention includes standing orders for syphilis serological testing whenever a male in HIV care undergoes HIV viral load testing, which typically occurs every 3-6 months. The control condition is the maintenance of current, provider-initiated syphilis testing practice. Approximately 3100 HIV-positive men will be followed over 30 months. Test results will be obtained from the centralized provincial laboratory in Ontario and will be supplemented by a standardized clinical worksheet and medical chart review at the clinics. Detailed clinical, psychosocial, and behavioral data is available for a subset of men receiving HIV care who are also participants of the province-wide Ontario HIV Treatment Network Cohort Study. Process evaluation plans include audit and feedback of compliance of the participating centers to identify potential barriers to the introduction of this type of practice into routine care. Health economic components include evaluation of the impact and cost-effectiveness of the intervention.Discussion: This trial will be the first of its kind in Canada and will provide evidence regarding the feasibility, clinical effectiveness, and cost-effectiveness of a clinic-based intervention to improve syphilis screening among HIV-positive men. Involvement of knowledge users in all stages of trial design, conduct, and analysis will facilitate scale-up should the intervention be effective.Trial Registration: ClinicalTrials.gov NCT02019043. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
13. Design and implementation of a sexual health intervention for migrant construction workers situated in Shanghai, China.
- Author
-
Mendelsohn, Joshua B., Calzavara, Liviana, Light, Lucia, Burchell, Ann N., Ren, Jinma, and Kang, Laiyi
- Abstract
Background: China's growing population of internal migrants has exceeded 236 million. Driven by rapid development and urbanization, this extreme population mobility creates opportunities for transmission of HIV and sexuallytransmitted infections (STI). Large numbers of rural migrants flock to megacities such as Shanghai in search of employment. Although migrants constitute a key population at heightened risk of acquiring HIV or an STI, there is a lack of easily accessible sexual health services available for them. In response, we designed a short, inexpensive sexual health intervention that sought to improve HIV and STI knowledge, while reducing stigma, risky sexual behaviour, and sexual transmission of HIV and STI among migrant construction workers (MCW) situated in Shanghai, China. Results: We implemented a three-armed, community-randomized trial spread across three administrative districts of Shanghai. The low-intensity intervention included educational pamphlets. The medium-intensity intervention included pamphlets, posters, and videos. The high-intensity intervention added group and individual counselling sessions. Across 18 construction sites, 1871 MCW were allocated at baseline to receive one intervention condition. Among baseline participants, 1304 workers were retained at 3-months, and 1013 workers were retained at 6-months, representing a total of 579 person-years of follow-up. All workers, regardless of participation, had access to informational materials even if they did not participate in the evaluation. Overall outputs included: 2284 pamphlets distributed, 720 posters displayed, 672 h of video shown, 376 participants accessed group counselling, and 61 participants attended individual counselling sessions. A multivariable analysis of participation found that men (aOR = 2.2; 95 % CI 1.1, 4.1; p = 0.036), workers situated in Huangpu district (aOR = 5.0; 95 % CI 2.6, 9.5; p < 0.001), and those with a middle school education (aOR = 1.9; 95 % CI 1.2, 3.0; p = 0.01) were more likely to have participated in intervention activities. Conclusion: A brief educational intervention that prioritized ease of delivery to a highly mobile workforce was feasible and easily accessed by participants. Routine implementation of sexual health interventions in workplaces that employ migrant labour have the potential to make important contributions toward improving HIV and STI outcomes among migrant workers in China's largest cities. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
14. Factors associated with the frequency of monitoring of liver enzymes, renal function and lipid laboratory markers among individuals initiating combination antiretroviral therapy: a cohort study.
- Author
-
Gillis, Jennifer, Bayoumi, Ahmed M., Burchell, Ann N., Cooper, Curtis, Klein, Marina B., Loutfy, Mona, Machouf, Nima, Montaner, Julio S. G., Tsoukas, Chris, Hogg, Robert S., Raboud, Janet, Montaner, Julio Sg, and Canadian Observational Cohort (CANOC) collaboration
- Subjects
ENZYME analysis ,INTRAVENOUS drug abuse ,HEPATITIS C ,HIV infections ,KIDNEY function tests ,LIPIDS ,LIVER ,LONGITUDINAL method ,RESEARCH funding ,HIGHLY active antiretroviral therapy ,ANTI-HIV agents ,MIXED infections ,DISEASE complications - Abstract
Background: As the average age of the HIV-positive population increases, there is increasing need to monitor patients for the development of comorbidities as well as for drug toxicities.Methods: We examined factors associated with the frequency of measurement of liver enzymes, renal function tests, and lipid levels among participants of the Canadian Observational Cohort (CANOC) collaboration which follows people who initiated HIV antiretroviral therapy in 2000 or later. We used zero-inflated negative binomial regression models to examine the associations of demographic and clinical characteristics with the rates of measurement during follow-up. Generalized estimating equations with a logit link were used to examine factors associated with gaps of 12 months or more between measurements.Results: Electronic laboratory data were available for 3940 of 7718 CANOC participants. The median duration of electronic follow-up was 3.5 years. The median (interquartile) rates of tests per year were 2.76 (1.60, 3.73), 2.55 (1.44, 3.38) and 1.42 (0.50, 2.52) for liver, renal and lipid parameters, respectively. In multivariable zero-inflated negative binomial regression models, individuals infected through injection drug use (IDU) were significantly less likely to have any measurements. Among participants with at least one measurement, rates of measurement of liver, renal and lipid tests were significantly lower for younger individuals and Aboriginal Peoples. Hepatitis C co-infected individuals with a history of IDU had lower rates of measurement and were at greater risk of having 12 month gaps between measurements.Conclusions: Hepatitis C co-infected participants infected through IDU were at increased risk of gaps in testing, despite publicly funded health care and increased risk of comorbid conditions. This should be taken into consideration in analyses examining factors associated with outcomes based on laboratory parameters. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
15. High incidence of diagnosis with syphilis co-infection among men who have sex with men in an HIV cohort in Ontario, Canada.
- Author
-
Burchell, Ann N., Allen, Vanessa G., Gardner, Sandra L., Moravan, Veronika, Tan, Darrell H. S., Grewal, Ramandip, Raboud, Janet, Bayoumi, Ahmed M., Kaul, Rupert, Mazzulli, Tony, McGee, Frank, and Rourke, Sean B.
- Subjects
- *
HIV-positive gay men , *SYPHILIS , *MEN who have sex with men , *MEDICAL care , *PUBLIC health , *HEALTH - Abstract
Background: The re-emergence of syphilis among HIV-positive gay and other men who have sex with men (MSM) requires vigilance. We estimated incidence of and risk factors for first and subsequent syphilis diagnoses among MSM in HIV care in Ontario, Canada. Methods: We analyzed data from 2,280 MSM under follow-up from 2006 to 2010 in the Ontario HIV Treatment Network Cohort Study (OCS), a multi-site clinical cohort. We obtained syphilis serology results via record linkage with the provincial public health laboratory. Rates were calculated using Poisson regression. Results: First syphilis diagnoses occurred at a rate of 2.0 per 100 person-years (95 % CI 1.7, 2.4; 121 cases) whereas the re-diagnosis rate was 7.5 per 100 person-years (95 % CI 6.3, 8.8; 136 cases). We observed higher rates over time and among men who were aged <30 years, receiving care in the two largest urban centers, or had a previous syphilis diagnosis. Syphilis diagnosis was less common among Indigenous men, men with higher CD4 cell counts, and, for first diagnoses only, among men with less than high school education. Conclusions: Compared to reported cases in the general male population, incidence of a new syphilis diagnosis was over 300 times greater among HIV-positive MSM but year-to-year changes reflected provincial trends. Re-diagnosis was common, suggesting treatment failure or re-infection. Novel syphilis control efforts are needed among HIV-positive MSM. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
16. Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada.
- Author
-
Patterson, Sophie, Cescon, Angela, Samji, Hasina, Keith Chan, Wendy Zhang, Raboud, Janet, Burchell, Ann N., Cooper, Curtis, Klein, Marina B., Rourke, Sean B., Loutfy, Mona R., Machouf, Nima, Montaner, Julio S. G., Tsoukas, Chris, and Hogg, Robert S.
- Subjects
LIFE expectancy ,ANTIRETROVIRAL agents ,DIAGNOSIS of HIV infections ,MEDICAL care of HIV-positive persons ,INTRAVENOUS injections ,PHYSIOLOGY - Abstract
Background: We sought to evaluate life expectancy and mortality of HIV-positive individuals initiating combination antiretroviral therapy (ART) across Canada, and to consider the potential error introduced by participant loss to follow-up (LTFU). Methods: Our study used data from the Canadian Observational Cohort (CANOC) collaboration, including HIV-positive individuals aged ≥18 years who initiated ART on or after January 1, 2000. The CANOC collaboration collates data from eight sites in British Columbia, Ontario, and Quebec. We computed abridged life-tables and remaining life expectancies at age 20 and compared outcomes by calendar period and patient characteristics at treatment initiation. To correct for potential underreporting of mortality due to participant LTFU, we conservatively estimated 30 % mortality among participants lost to follow-up. Results: 9997 individuals contributed 49,589 person-years and 830 deaths for a crude mortality rate of 16.7 [standard error (SE) 0.6] per 1000 person-years. When assigning death to 30 % of participants lost to follow-up, we estimated 1170 deaths and a mortality rate of 23.6 [SE 0.7] per 1000 person-years. The crude overall life expectancy at age 20 was 45.2 [SE 0.7] and 37.5 [SE 0.6] years after adjusting for LTFU. In the LTFU-adjusted analysis, lower life expectancy at age 20 was observed for women compared to men (32.4 [SE 1.1] vs. 39.2 [SE 0.7] years), for participants with injection drug use (IDU) history compared to those without IDU history (23.9 [SE 1.0] vs. 52.3 [SE 0.8] years), for participants reporting Aboriginal ancestry compared to those with no Aboriginal ancestry (17.7 [SE 1.5] vs. 51.2 [SE 1.0] years), and for participants with CD4 count <350 cells/μL compared to CD4 count ≥350 cells/μL at treatment initiation (36.3 [SE 0.7] vs. 43.5 [SE 1.3] years). Life expectancy at age 20 in the calendar period 2000-2003 was lower than in periods 2004-2007 and 2008-2012 in the LTFU-adjusted analyses (30.8 [SE 0.9] vs. 38.6 [SE 1.0] and 54.2 [SE 1.4]). Conclusions: Life expectancy and mortality for HIV-positive individuals receiving ART differ by calendar period and patient characteristics at treatment initiation. Failure to consider LTFU may result in underestimation of mortality rates and overestimation of life expectancy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
17. Colorectal cancer among persons with HIV: protocol for a systematic review and meta-analysis.
- Author
-
Djiometio Nguemo, Joseph, O'Neill, Tyler J., Kou, Nancy, Tynan, Anne-Marie, Agha, Ayda, Burchell, Ann N., and Antoniou, Tony
- Subjects
COLON cancer ,META-analysis ,QUANTITATIVE research ,PSYCHOMETRICS ,ONCOLOGY - Abstract
Background: As persons with HIV live longer, data regarding the epidemiology of colorectal cancer are required to optimize the long-term management of these patients. The purpose of this systematic review and meta-analysis is to synthesize evidence regarding the incidence of colorectal cancer in persons with HIV. Methods/design: Our primary outcome is the standardized incidence ratio of colorectal cancer among persons with HIV relative to rates in persons not living with HIV. Our secondary objectives are to summarize the evidence for differences with respect to stage at diagnosis, site of disease, and mortality due to colorectal cancer. We will search electronic bibliographic databases from their inception date, as well as conference proceedings and reference lists of included articles. Two investigators will independently screen citations and full-text articles, conduct data abstraction, and appraise study quality. We will examine clinical, methodological, and statistical heterogeneity among studies prior to conducting meta-analysis. Random effects meta-analysis methods will be employed to estimate standardized incidence ratios. These data will inform the development of guidelines for colorectal cancer screening in persons with HIV. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
18. Patterns of syphilis testing in a large cohort of HIV patients in Ontario, Canada, 2000-2009.
- Author
-
Burchell, Ann N., Allen, Vanessa G., Moravan, Veronika, Gardner, Sandra, Raboud, Janet, Tan, Darrell H. S., Bayoumi, Ahmed M., Kaul, Rupert, Mazzulli, Tony, McGee, Frank, Millson, Peggy, Remis, Robert S., and Rourke, Sean B.
- Subjects
- *
DIAGNOSIS of syphilis , *HIV infection risk factors , *HIV-positive persons , *MEN who have sex with men , *DISEASES - Abstract
Background: Since 2000, reported syphilis cases increased ten-fold in Canada, particularly among men who have sex with men (MSM) co-infected with HIV. We characterized temporal patterns of of syphilis testing in a large cohort of HIV patients in Ontario, Canada. Methods: We analyzed data from a multi-site cohort of people in HIV care from 2000 to 2009. Data were obtained from medical charts, interviews and record linkage with the syphilis test database at the Public Health Ontario Laboratories. We estimated the proportion that had syphilis testing at least once per year and the period and annual prevalence of reactive tests. Results: Among 4232 participants, the annual proportion tested rose from 2.7% (95%CI 1.9, 3.5) in 2000 to 54.6% (95%CI 52.9, 56.3) in 2009. Testing was most common for participants who were men who have sex with men (MSM), aged <30, recently diagnosed with HIV, were antiretroviral treatment naive, had routine HIV lab testing at least twice in that year, or tested for syphilis in the preceding year. The proportion with at least one reactive test in 2000-09 was 21.0% (95%CI 19.4, 22.7) for MSM, 5.3% (95%CI 3.3, 7.4) for non-MSM males, and 2.6% (95%CI 1.2, 4.0) for women. Among MSM, the annual prevalence of reactive syphilis tests with high RPR titre (⩾1:16) peaked at 3.8% in 2009. Conclusions: The burden of syphilis co-infection rose considerably among HIV-positive MSM, such that by 2009, at least 1 in 5 men had laboratory evidence of current or past infection. Interventions may be needed to boost syphilis testing to achieve goals set by guidelines even in settings with universal health care. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
19. Representativeness of an HIV cohort of the sites from which it is recruiting: results from the Ontario HIV Treatment Network (OHTN) cohort study.
- Author
-
Raboud, Janet, DeSheng Su, Burchell, Ann N., Gardner, Sandra, Walmsley, Sharon, Bayoumi, Ahmed M., Blitz, Sandra, Cooper, Curtis, Salit, Irving, Cohen, Jeff, Rourke, Sean B., and Loutfy, Mona R.
- Subjects
HIV infections ,THERAPEUTICS ,EPIDEMIOLOGY ,COHORT analysis ,GENERALIZABILITY theory ,COMPARATIVE studies ,REGRESSION analysis ,VIRAL load - Abstract
Background: Participation bias is a well-known phenomenon in epidemiologic research, where individuals consenting to research studies differ from individuals who are not able or willing to participate. These dissimilarities may limit the generalizability of results of research studies. Quantification of the participation bias is essential for the interpretation of research findings. Methods: The Ontario HIV Treatment Network Cohort Study (OCS) is an ongoing open cohort study of HIV positive individuals receiving care at one of 11 sites in Ontario. OCS participants from 4 sites were compared to nonparticipants (those who declined or were not approached) at those sites with regard to gender, age, HIV risk factor, CD4 count and viral load (VL). Generalized logit regression models were used to identify predictors of declining to participate or not being approached to participate. Results: Compared to participants (P) in the OCS, individuals who declined to participate (D) and those who were not approached (NA) were slightly younger (D:45, NA:44 vs P:46), less likely to be male (D: 71%, NA:75% vs P:88%), less likely to be Caucasian (D:41%, NA:57% vs P:72%) and less likely to be Canadian-born (D: 39%, NA: 52% vs P: 69%). Patients who were not approached to participate were less likely to have VL < 50 copies/mL than other patients (D: 75%, NA: 62%, P: 74%) and had lower CD4 counts than OCS participants (D: 450 cells/mm³, NA: 420 cells/mm³, P: 480 cells/mm³). Conclusions: Significant demographic and clinical differences were found between OCS participants and non-participants. Extrapolation of research findings to other populations should be undertaken cautiously. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
20. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy
- Author
-
Rossi, Carmine, Raboud, Janet, Walmsley, Sharon, Cooper, Curtis, Antoniou, Tony, Burchell, Ann N, Hull, Mark, Chia, Jason, Hogg, Robert S, Moodie, Erica E, and Klein, Marina B
- Subjects
virus diseases ,3. Good health - Abstract
Background: Combination antiretroviral therapy (cART) has reduced mortality from AIDS-related illnesses and chronic comorbidities have become prevalent among HIV-infected patients. We examined the association between hepatitis C virus (HCV) co-infection and chronic kidney disease (CKD) among patients initiating modern antiretroviral therapy. Methods: Data were obtained from the Canadian HIV Observational Cohort for individuals initiating cART from 2000 to 2012. Incident CKD was defined as two consecutive serum creatinine-based estimated glomerular filtration (eGFR) measurements 60 mL/min/1.73m2 at cART initiation, of which 19% were HCV co-infected. One hundred and fifty patients developed CKD during 10,903 person-years of follow-up (PYFU). The CKD incidence rate was higher among co-infected than HIV mono-infected patients (26.0 per 1000 PYFU vs. 10.7 per 1000 PYFU). After adjusting for demographics, virologic parameters and traditional CKD risk factors, HCV co-infection was associated with a significantly shorter time to incident CKD (HR 1.97; 95% CI: 1.33, 2.90). Additional factors associated with incident CKD were female sex, increasing age after 40 years, lower baseline eGFR below 100 mL/min/1.73m2, increasing HIV viral load and cumulative exposure to tenofovir and lopinavir. Conclusions: HCV co-infection was associated with an increased risk of incident CKD among HIV-infected patients initiating cART. HCV-HIV co-infected patients should be monitored for kidney disease and may benefit from available HCV treatments.
21. Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
- Author
-
Antoniou, Tony, Szadkowski, Leah, Walmsley, Sharon, Cooper, Curtis, Burchell, Ann N, Bayoumi, Ahmed M, Montaner, Julio S G, Loutfy, Mona, Klein, Marina B, Machouf, Nima, Tsoukas, Christos, Wong, Alexander, Hogg, Robert S, and Raboud, Janet
- Subjects
immune system diseases ,parasitic diseases ,virus diseases ,heterocyclic compounds ,biochemical phenomena, metabolism, and nutrition ,3. Good health - Abstract
Background: Atazanavir/ritonavir and darunavir/ritonavir are common protease inhibitor-based regimens for treating patients with HIV. Studies comparing these drugs in clinical practice are lacking. Methods: We conducted a retrospective cohort study of antiretroviral naïve participants in the Canadian Observational Cohort (CANOC) collaboration initiating atazanavir/ritonavir- or darunavir/ritonavir-based treatment. We used separate Fine and Gray competing risk regression models to compare times to regimen failure (composite of virologic failure or discontinuation for any reason). Additional endpoints included virologic failure, discontinuation due to virologic failure, discontinuation for other reasons, and virologic suppression. Results: We studied 222 patients treated with darunavir/ritonavir and 1791 patients treated with atazanavir/ritonavir. Following multivariable adjustment, there was no difference between darunavir/ritonavir and atazanavir-ritonavir in the risk of regimen failure (adjusted hazard ratio 0.76, 95% CI 0.56 to 1.03) Darunavir/ritonavir-treated patients were at lower risk of virologic failure relative to atazanavir/ritonavir treated patients (aHR 0.50, 95% CI 0.28 to 0.91), findings driven largely by high rates of virologic failure among atazanavir/ritonavir-treated patients in the province of British Columbia. Of 108 discontinuations due to virologic failure, all occurred in patients starting atazanavir/ritonavir. There was no difference between regimens in time to discontinuation for reasons other than virologic failure (aHR 0.93; 95% CI 0.65 to 1.33) or virologic suppression (aHR 0.99, 95% CI 0.82 to 1.21). Conclusions: The risk of regimen failure was similar between patients treated with darunavir/ritonavir and atazanavir/ritonavir. Although darunavir/ritonavir was associated with a lower risk of virologic failure relative to atazanavir/ritonavir, this difference varied substantially by Canadian province and likely reflects regional variation in prescribing practices and patient characteristics.
22. Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada
- Author
-
Patterson, Sophie, Cescon, Angela, Samji, Hasina, Chan, Keith, Zhang, Wendy, Raboud, Janet, Burchell, Ann N, Cooper, Curtis, Klein, Marina B, Rourke, Sean B, Loutfy, Mona R, Machouf, Nima, Montaner, Julio S G, Tsoukas, Chris, and Hogg, Robert S
- Subjects
3. Good health - Abstract
Background: We sought to evaluate life expectancy and mortality of HIV-positive individuals initiating combination antiretroviral therapy (ART) across Canada, and to consider the potential error introduced by participant loss to follow-up (LTFU). Methods Our study used data from the Canadian Observational Cohort (CANOC) collaboration, including HIV-positive individuals aged ≥18 years who initiated ART on or after January 1, 2000. The CANOC collaboration collates data from eight sites in British Columbia, Ontario, and Quebec. We computed abridged life-tables and remaining life expectancies at age 20 and compared outcomes by calendar period and patient characteristics at treatment initiation. To correct for potential underreporting of mortality due to participant LTFU, we conservatively estimated 30 % mortality among participants lost to follow-up. Results 9997 individuals contributed 49,589 person-years and 830 deaths for a crude mortality rate of 16.7 [standard error (SE) 0.6] per 1000 person-years. When assigning death to 30 % of participants lost to follow-up, we estimated 1170 deaths and a mortality rate of 23.6 [SE 0.7] per 1000 person-years. The crude overall life expectancy at age 20 was 45.2 [SE 0.7] and 37.5 [SE 0.6] years after adjusting for LTFU. In the LTFU-adjusted analysis, lower life expectancy at age 20 was observed for women compared to men (32.4 [SE 1.1] vs. 39.2 [SE 0.7] years), for participants with injection drug use (IDU) history compared to those without IDU history (23.9 [SE 1.0] vs. 52.3 [SE 0.8] years), for participants reporting Aboriginal ancestry compared to those with no Aboriginal ancestry (17.7 [SE 1.5] vs. 51.2 [SE 1.0] years), and for participants with CD4 count
23. Colorectal cancer among persons with HIV: protocol for a systematic review and meta-analysis.
- Author
-
Nguemo JD, O'Neill TJ, Kou N, Tynan AM, Agha A, Burchell AN, and Antoniou T
- Subjects
- Humans, Systematic Reviews as Topic, Colorectal Neoplasms complications, HIV Infections complications
- Abstract
Background: As persons with HIV live longer, data regarding the epidemiology of colorectal cancer are required to optimize the long-term management of these patients. The purpose of this systematic review and meta-analysis is to synthesize evidence regarding the incidence of colorectal cancer in persons with HIV., Methods/design: Our primary outcome is the standardized incidence ratio of colorectal cancer among persons with HIV relative to rates in persons not living with HIV. Our secondary objectives are to summarize the evidence for differences with respect to stage at diagnosis, site of disease, and mortality due to colorectal cancer. We will search electronic bibliographic databases from their inception date, as well as conference proceedings and reference lists of included articles. Two investigators will independently screen citations and full-text articles, conduct data abstraction, and appraise study quality. We will examine clinical, methodological, and statistical heterogeneity among studies prior to conducting meta-analysis. Random effects meta-analysis methods will be employed to estimate standardized incidence ratios. These data will inform the development of guidelines for colorectal cancer screening in persons with HIV., Systematic Review Registration: PROSPERO CRD42014013449.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.